Anti-myelin-associated glycoprotein peripheral neuropathy as the only presentation of low grade lymphoma: a case report

Peripheral nervous system involvement has been reported in systemic B or T cell lymphoma and may result from many mechanisms. We present a case of 59-year-old Caucasian man presented with a three years history of progressively worsening peripheral neuropathy with no obvious reason. An extensive workup revealed anti-myelin-associated glycoprotein neuropathy as the only presenting feature of low grade B cell Lymphoma

Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases

BACKGROUND: Cytotoxic therapy for relapsed and refractory germ cell tumors or metastatic sex cord stromal tumors is rarely effective and is often accompanied by high adverse event rates. Expression of CD30 has been observed in testicular cancers, and patients with CD30-expressing embryonal carcinomas have worse progression-free survival and overall survival than those with CD30-negative tumors. The objective of this study (NCT01461538) was to characterize the antitumor activity of brentuximab vedotin in patients with CD30-expressing nonlymphomatous malignancies. Enrolled patients included seven patients with relapsed or refractory germ cell tumors or metastatic sex cord stromal tumors described in this case series. MATERIALS AND METHODS: Forty patients with relapsed or refractory germ cell tumors, metastatic sex cord stromal tumors, or testicular tumors were screened for CD30 expression; 14 patients had tumors that expressed CD30. Seven patients with CD30-expressing testicular cancer were enrolled in the treatment study: five patients with germ cell tumors, one patient with a Leydig cell tumor, and one patient with a Sertoli cell tumor. Patients were treated with brentuximab vedotin at initial doses of 1.8 or 2.4 mg/kg every 3 weeks. Response assessments were performed at cycles 2 and 4 and every 4 cycles thereafter while the patient was receiving treatment. RESULTS: Two of seven patients achieved an objective response, including one durable complete response and one partial response at a single time point. Both responding patients had germ cell tumors. Treatment with brentuximab vedotin was generally well tolerated. CONCLUSION: Treatment of relapsed or refractory germ cell tumors with brentuximab vedotin can induce durable responses with a manageable toxicity profile. IMPLICATIONS FOR PRACTICE: This case series of seven patients with relapsed or refractory CD30-expressing germ cell tumors (GCTs) or sex cord stromal tumors demonstrates that brentuximab vedotin has activity against GCTs and is well tolerated in heavily pretreated patients with these aggressive tumor types. One patient achieved a complete response that has been durable for almost 4 years since the discontinuation of treatment with brentuximab vedotin. Therefore, brentuximab vedotin may be a valuable option for physicians who care for this difficult-to-treat patient population

The Causal Relationship between Financial Development and Economic Performance in Tanzania

The study employs cointegration, vector error correction model and Granger causality test to ascertain causation between financial development and economic performance in Tanzania. Economic performance is measured by the real GDP, whereas proxies for financial development are: the ratio of money supply to nominal GDP; and growth of credit to private sector. The results show that there is a stable long-run relationship between financial development and economic performance in Tanzania. Granger causality test indicates that the causality runs from financial development to economic performance.Keywords: Growth, credit to private sector, money supply, financial developmen

Management of Chemotherapy Induced Nausea and Vomiting in Patients on Multiday Cisplatin Based Combination Chemotherapy

Introduction of cisplatin based chemotherapy has revolutionized the treatment of germ cell tumors. A common side effect of multiday cisplatin chemotherapy is severe nausea and vomiting. Considerable progress has been made in the control of these side effects since the introduction of cisplatin based chemotherapy in the 1970s. Germ cell tumor which is a model for a curable neoplasm has also turned into an excellent testing ground to develop effective strategies to prevent chemotherapy induced nausea and vomiting (CINV) in multiday cisplatin based regimens. The use of combination of a 5-hydroxytryptamine (HT)3 receptor antagonist, a neurokinin-1 (NK1) antagonist, and dexamethasone has greatly improved our ability to prevent and control acute and delayed CINV. Mechanism and pattern of CINV with multiday chemotherapy may differ from those in single day chemotherapy and therefore efficacy of antiemetic drugs as observed in single day chemotherapy may not be applicable. There are only few randomized clinical trials with special emphasis on multiday chemotherapy. Further studies are essential to determine the efficacy, optimal dose, and duration of the newer agents and combinations in multiday cisplatin based chemotherapy

Performance of a multianalyte \u27rule-out\u27 assay in pregnant individuals with suspected preeclampsia

BACKGROUND: The ability to diagnose preeclampsia clinically is suboptimal. Our objective was to validate a novel multianalyte assay and characterize its performance, when intended for use as an aid to rule-out preeclampsia. METHODS: Prospective, multicenter cohort study of pregnant individuals presenting between 28 RESULTS: One thousand thirty-six pregnant individuals were enrolled in the study cohort with an incidence of preeclampsia of 30.3% (27.6%-33.2%). The time to develop preeclampsia was shorter for those with an at-risk compared with negative assay result (log-rank CONCLUSIONS: We confirmed that a novel multianalyte assay was associated with the time to develop preeclampsia and has a moderate sensitivity and negative likelihood ratio but high negative predictive value when assessed as an aid to rule out preeclampsia within 7 days of enrollment. REGISTRATION: The study was registered on Clinicaltrials.gov (Identifier NCT02780414)

Reducing complexity and improving the reliability of frequency reconfigurable antennas

In this paper the complexity and reliability of frequency reconfigurable antennas are presented. A new approach for decreasing the complexity of reconfigurable antennas while maintaining the reliability of such structures is discussed. An example is given to prove the validity of the proposed approaches

Structural Architectures for a Deployable Wideband UHF Antenna

This paper explores concepts for a wideband deployable antenna suitable for small satellites. The general approach taken was to closely couple antenna theory and structural mechanics, to produce a deployable antenna that is considered efficient in both fields. Approaches that can be deployed using stored elastic strain energy have been favored over those that require powered actuators or environmental effects to enforce deployment. Two types of concepts were developed: thin shell structure and pantograph. These concepts cover four antenna topologies: crossed log periodic, conical log spiral, helical and quadrifilar helix. Of these, the conical log spiral antenna and the accompanying deployment concepts are determined to be the most promising approaches that warrant further study

Analyzing capacitor-based reconfigurable antennas using graph models

This paper discusses reconfigurable antennas using variable capacitors or varactors to achieve reconfiguration. We propose graph models as tools to understand reconfigurable antenna topologies and their configurations. Guidelines are set to model this type of reconfigurable antennas using graphs and examples are studied to investigate their optimal performance